Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells
Cornelia Brendel(Philipps University of Marburg), Andreas Neubauer(RWTH Aachen University), Suneet Shukla(National Cancer Institute), Robert W. Robey(National Institutes of Health), Andreas Burchert(Philipps University of Marburg), Marius Dohse(Center for Cancer Research), Suresh V. Ambudkar(National Institutes of Health), Ulrich Boudriot(Philipps University of Marburg), Ying Wang(Third Affiliated Hospital of Guangzhou Medical University), Susan E. Bates(The Nature Conservancy), Christian Scharenberg(National Institutes of Health), Gunther Wennemuth(Saarland University)
Cited by 200
Related Papers
Diverse Applications of Nanomedicine
|ACS Nano|2017|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance
|Cellular and Molecular Life Sciences|2001|685
Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)
|Journal of Clinical Oncology|2005|573